Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
Epistemonikos ID: 9865304e3add092f0fc4317ade8da53f1eab8222
First added on: May 04, 2024